All Stories

  1. Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA‐matched unrelated donor HCT in paediatric acute leukaemia
  2. Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee
  3. Increased Donor Inhibitory KIR Are Associated with Reduced GVHD and Improved Survival Following HLA Matched Unrelated Donor HCT in Pediatric Acute Leukemia
  4. INTRAVENOUS VITAMIN C SUPPLEMENTATION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: SALUTARY IMPACT ON CLINICAL OUTCOMES
  5. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study
  6. Cell‐free next‐generation sequencing impacts diagnosis and antimicrobial therapy in immunocompromised hosts: A retrospective study
  7. Allogeneic haematopoietic cell transplants as dynamical systems: influence of early‐term immune milieu on long‐term T‐cell recovery
  8. DNA Methylation Changes in Autologous Hematopoietic Stem Cell Transplant Patients
  9. Engraftment syndrome after allogeneic stem cell transplantation: a systematic review and meta-analysis
  10. Dynamical Systems Modeling of Early-Term Immune Reconstitution with Different Antithymocyte Globulin Administration Schedules in Allogeneic Stem Cell Transplantation
  11. Transient left ventricular dysfunction following chimeric antigen receptor T‐cell‐mediated encephalopathy: A form of stress cardiomyopathy
  12. High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation
  13. Correction: Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML
  14. Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
  15. Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML
  16. What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti‐thymocyte globulin?
  17. On the Order of Gene Distribution on Chromosomes Across the Animal Kingdom
  18. Reduced plasma ascorbic acid levels in recipients of myeloablative conditioning and hematopoietic cell transplantation
  19. Hematopoietic stem cell mobilization following PD‐1 blockade: Cytokine release syndrome after transplantation managed with ascorbic acid
  20. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy
  21. Are We Overlooking the Use of Oral Ribavirin for Respiratory Syncytial Virus Infection Following Hematopoietic Stem Cell Transplantation?
  22. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies
  23. The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation
  24. Reconstituting donor T cells increase their biomass following hematopoietic stem cell transplantation
  25. Conditioning neoadjuvant therapies for improved immunotherapy of cancer
  26. Dynamical system modeling to simulate donor T cell response to whole exome sequencing-derived recipient peptides: Understanding randomness in alloreactivity incidence following stem cell transplantation
  27. DNA nanomapping using CRISPR-Cas9 as a programmable nanoparticle
  28. Sequence homology between HLA-bound cytomegalovirus and human peptides: A potential trigger for alloreactivity
  29. Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis
  30. Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model
  31. Treatment of acute fibrinous organizing pneumonia following hematopoietic cell transplantation with etanercept
  32. The Influence of Lymphoid Reconstitution Kinetics on Clinical Outcomes in Allogeneic Stem Cell Transplantation
  33. Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential in HLA-Matched and -Mismatched Donor–Recipient Pairs
  34. Stem Cell Transplantation as a Shattering Event: Meaning Making, Coping and Adjustment
  35. Enhanced Immunosuppression Free Survival in Matched Related Donor Hematopoietic Cell Transplant Recipients Conditioned with Anti-Thymocyte Globulin
  36. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells
  37. On the organization of human T-cell receptor loci: log-periodic distribution of T-cell receptor gene segments
  38. Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential In HLA-Matched and Mismatched Donor-Recipient Pairs
  39. Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes
  40. Dynamical System Modeling of Immune Reconstitution Following Allogeneic Stem Cell Transplantation (SCT) Conditioned with Rabbit Anti-Thymocyte Globulin
  41. On The Organization Of Human T Cell Receptor Loci.
  42. Stem Cell Transplantation as a Dynamical System: Are Clinical Outcomes Deterministic?
  43. In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation
  44. Etiology of GVHD: Alloreactivity or Impaired Cellular Adaptation?
  45. Whole exome sequencing to estimate alloreactivity potential between donors and recipients in stem cell transplantation
  46. In Silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem Cell Transplant Donor-Recipient Pairs
  47. Fractal Organization of the Human T Cell Repertoire in Health and after Stem Cell Transplantation
  48. An Outcome-Adaptive Allocation Method for Clinical Trials With Dual Binary Objectives
  49. Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity
  50. Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients
  51. Favorable Outcomes in Patients with High Donor-Derived T Cell Count after In Vivo T Cell–Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation
  52. Distinct Oligoclonal T Cells Are Associated With Graft Versus Host Disease After Stem-Cell Transplantation
  53. Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk
  54. Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse
  55. Comment on “Cutting Edge: CD8+ T Cell Priming in the Absence of NK Cells Leads to Enhanced Memory Responses”
  56. Distinct Oligoclonal T Cells Are Associated With GVHD or GVHD-Free Responses in Patients With Hematologic Malignancies Following Stem Cell Transplantation
  57. <em>Ex vivo</em> Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
  58. Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation
  59. Rearrangements of theMLLgene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding
  60. Dose intense therapy for relapsed lymphoproliferative disorders: the more things change, the more they are the same
  61. Impaired NHEJ function in multiple myeloma
  62. Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT
  63. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections
  64. Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma
  65. Alefacept in corticosteroid refractory graft versus host disease: Early results indicate promising activity
  66. Autologous hematopoietic stem cell transplants that utilize total body irradiation can safely be carried out entirely on an outpatient basis
  67. Cardiac nonamyloidotic immunoglobulin deposition disease
  68. Patients' understanding of disease status and treatment plan at initial hematopoietic stem cell transplantation consultation
  69. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma
  70. The Administration of Polymerized Human Hemoglobin (Pyridoxylated) to a Jehovah's Witness After Submyeloablative Stem Cell Transplantation Complicated by Delayed Graft Failure
  71. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines
  72. Second allografts for relapsed hematologic malignancies: feasibility of using a different donor
  73. Post-transplant air-leak syndrome
  74. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma
  75. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective
  76. Infection - an underappreciated cause of bone pain in multiple myeloma
  77. Clinical activity of arsenic trioxide for the treatment of multiple myeloma
  78. Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
  79. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations
  80. Acquired factor VII deficiency in hematopoietic stem cell transplant recipients
  81. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning
  82. Predicting long-term (≥ 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants
  83. Infections during mobilizing chemotherapy and following autologous stem cell transplantation
  84. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
  85. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
  86. T-cell factor-1 expression during human natural killer cell development and in circulating CD56+ bright natural killer cells
  87. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone